

# Manish A Shah

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5704598/publications.pdf>

Version: 2024-02-01

237  
papers

16,463  
citations

24978

57  
h-index

17055

122  
g-index

240  
all docs

240  
docs citations

240  
times ranked

17014  
citing authors

#	ARTICLE	IF	CITATIONS
1	Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. JCO Oncology Practice, 2022, 18, 35-41.	1.4	12
2	Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2- advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study.. Journal of Clinical Oncology, 2022, 40, TPS365-TPS365.	0.8	5
3	Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers, 2022, 14, 1168.	1.7	0
4	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research, 2022, 28, 3686-3694.	3.2	1
5	First clinical and immunogenicity results including all subjects enrolled in a phase I study of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI).. Journal of Clinical Oncology, 2022, 40, 2515-2515.	0.8	4
6	Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) ILUSTRO Cohort 3.. Journal of Clinical Oncology, 2021, 39, TPS260-TPS260.	0.8	5
7	Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.. Journal of Clinical Oncology, 2021, 39, 168-168.	0.8	5
8	Reply to K. de Joode et al. Journal of Clinical Oncology, 2021, 39, 1093-1094.	0.8	0
9	Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). Journal of Clinical Oncology, 2021, 39, 990-1000.	0.8	30
10	KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncology, 2021, 17, 1143-1153.	1.1	63
11	Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC).. Journal of Clinical Oncology, 2021, 39, 4005-4005.	0.8	18
12	Prognostic impact of pSTAT3 on overall survival (OS) in gastrointestinal (GI) cancers: Data from 3 phase 3, randomized controlled trials (RCTs).. Journal of Clinical Oncology, 2021, 39, 4147-4147.	0.8	0
13	Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.. Journal of Clinical Oncology, 2021, 39, e16063-e16063.	0.8	6
14	A phase II study of short course FOLFOX chemotherapy with either nivolumab (Nivo) or Nivo plus radiation in the first line treatment of metastatic or unresectable gastroesophageal (GEA) cancers.. Journal of Clinical Oncology, 2021, 39, TPS4157-TPS4157.	0.8	0
15	Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. Communications Biology, 2021, 4, 785.	2.0	3
16	Development of the Oncolo-GIST (Giving Information Strategically & Transparently) Intervention Manual for Oncologist Skills Training in Advanced Cancer Prognostic Information Communication. Journal of Pain and Symptom Management, 2021, 62, 10-19.e4.	0.6	9
17	Abstract 3182: Tumor immune microenvironment based molecular functional clustering reveals a prognostic signature that predicts overall survival in patients with gastric cancer. , 2021, , .		0
18	Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet, The, 2021, 398, 759-771.	6.3	642

#	ARTICLE	IF	CITATIONS
19	Dietary fructose improves intestinal cell survival and nutrient absorption. <i>Nature</i> , 2021, 597, 263-267.	13.7	133
20	Implications of reactive oxygen species on cancer formation and its treatment. <i>Seminars in Oncology</i> , 2021, 48, 238-245.	0.8	33
21	Validation of a Circulating Tumor <scp>DNA</scp>-Based <scp>Next-Generation</scp> Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. <i>Oncologist</i> , 2021, 26, e1971-e1981.	1.9	11
22	Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer. <i>Cell</i> , 2021, 184, 5015-5030.e16.	13.5	102
23	Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. <i>Oncologist</i> , 2021, 26, e1704-e1729.	1.9	14
24	Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3182-3184.	0.8	21
25	CLIP-170S is a microtubule-TIP variant that confers resistance to taxanes by impairing drug-target engagement. <i>Developmental Cell</i> , 2021, 56, 3264-3275.e7.	3.1	5
26	410â€¦Phase I interim study results of Nour-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI). , 2021, 9, A441-A441.		8
27	Randomized, open-label, phase 2 study of andeciximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival. , 2021, 9, e003580.		20
28	Palliative Chemotherapy or Radiation and Prognostic Understanding among Advanced Cancer Patients: The Role of Perceived Treatment Intent. <i>Journal of Palliative Medicine</i> , 2020, 23, 33-39.	0.6	15
29	ASCO Clinical Practice Guideline Endorsements and Adaptations. <i>Journal of Clinical Oncology</i> , 2020, 38, 834-840.	0.8	7
30	Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4138-4148.	0.8	614
31	Safety and Efficacy of Andeciximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study. <i>Oncologist</i> , 2020, 25, 954-962.	1.9	14
32	Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. , 2020, 8, e001006.		62
33	Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 349-354.	157.7	18
34	Metastatic Pancreatic Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 3217-3230.	0.8	151
35	Clinical Screening for COVID-19 in Asymptomatic Patients With Cancer. <i>JAMA Network Open</i> , 2020, 3, e2023121.	2.8	20
36	Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 2677-2694.	0.8	169

#	ARTICLE	IF	CITATIONS
37	Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome. <i>Clinical Cancer Research</i> , 2020, 26, 4756-4766.	3.2	7
38	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020, 130, 63-71.	1.3	15
39	Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3771-3783.	3.2	19
40	COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 3914-3924.	0.8	111
41	Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2 <sup>+</sup> /HER2 <sup>-</sup> advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4648-TPS4648.	0.8	3
42	Exploratory longitudinal analysis of cfDNA to reveal potential biomarkers of CRC progression and treatment response.. <i>Journal of Clinical Oncology</i> , 2020, 38, 207-207.	0.8	1
43	Identification of cancer hallmarks associated with benefit in advanced gastroesophageal adenocarcinoma patients treated with checkpoint blockade.. <i>Journal of Clinical Oncology</i> , 2020, 38, 439-439.	0.8	7
44	Phase II randomized controlled trial (RCT) of medical intensive nutrition therapy (MINT) to improve chemotherapy (CT) tolerability in malnourished patients with solid tumor malignancies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12090-12090.	0.8	0
45	Abstract 641: Systems biology identifies Gleevec as a specific inhibitor of CLIP-170S, a novel +TIP isoform, which causes taxane resistance in cancer cells and patients by obstructing the Microtubule pore. , 2020, , .		0
46	Abstract 2011: HER2 expression and M2-like tumor infiltrating macrophages associated with Cabazitaxel activity in gastric cancer. , 2020, , .		0
47	Abstract CT282: KEYNOTE-975: A randomized, double-blind, placebo-controlled phase 3 trial of pembrolizumab vs placebo in participants with esophageal carcinoma receiving concurrent definitive chemoradiotherapy. , 2020, , .		0
48	Abstract 975: Single cell RNA sequencing of esophageal adenocarcinoma before and after chemotherapy alone and with pembrolizumab identifies novel tumor immune microenvironment alterations. , 2020, , .		0
49	Comparative effectiveness of treatment modalities in non-metastatic gastric adenocarcinoma: a propensity score matching analysis of the National Cancer Database. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000483.	1.1	1
50	Abstract S10-01: COVID-19 severity and outcomes in hospitalized patients with cancer at a New York City tertiary medical center: A matched cohort study. , 2020, , .		0
51	261â€¦Association of T-cellâ€œinflamed gene expression profile and PD-L1 status with efficacy of pembrolizumab in patients with esophageal cancer from KEYNOTE-180. , 2020, , .		1
52	Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 355-362.	2.7	11
53	Anti-PD-1 therapy as monotherapy and the development of biomarkers for patient selection in gastroesophageal cancers. <i>Annals of Oncology</i> , 2019, 30, vi45.	0.6	0
54	Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1135-1141.	1.4	26

#	ARTICLE	IF	CITATIONS
55	The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986976.	1.4	31
56	A circadian clock is essential for homeostasis of group 3 innate lymphoid cells in the gut. <i>Science Immunology</i> , 2019, 4, .	5.6	71
57	Cancer-Specific Thresholds Adjust for Whole Exome Sequencingâ€Based Tumor Mutational Burden Distribution. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	21
58	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	24
59	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 420-435.	5.1	191
60	A Comparison of Homogenization vs. Enzymatic Lysis for Microbiome Profiling in Clinical Endoscopic Biopsy Tissue Samples. <i>Frontiers in Microbiology</i> , 2019, 9, 3246.	1.5	9
61	Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2019, 22, 803-816.	2.7	36
62	Optimizing Therapies in the Perioperative Management of Gastric Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 57.	1.3	13
63	Pharmacokinetic and exposureâ€response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 539-550.	1.1	7
64	Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e88-e95.	1.8	17
65	Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline Summary. <i>Journal of Oncology Practice</i> , 2019, 15, 290-292.	2.5	12
66	Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2. <i>Nature</i> , 2019, 568, 405-409.	13.7	199
67	Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline. <i>Journal of Global Oncology</i> , 2019, 5, 1-22.	0.5	39
68	Associations between Anxiety, Poor Prognosis, and Accurate Understanding of Scan Results among Advanced Cancer Patients. <i>Journal of Palliative Medicine</i> , 2019, 22, 961-965.	0.6	25
69	KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. <i>Future Oncology</i> , 2019, 15, 1057-1066.	1.1	132
70	Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus. <i>JAMA Oncology</i> , 2019, 5, 546.	3.4	366
71	Print and Digital Media Review. <i>Gastroenterology</i> , 2019, 156, 281-283.	0.6	0
72	Abstract 2826: Understanding associations among local microbiome, immune response, and efficacy of immunotherapy in esophageal cancer. , 2019, , .		2

#	ARTICLE	IF	CITATIONS
73	Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.. Journal of Clinical Oncology, 2019, 37, 4010-4010.	0.8	38
74	Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study.. Journal of Clinical Oncology, 2019, 37, 4032-4032.	0.8	4
75	Phase II study of a telomerase-specific oncolytic adenovirus (OBP-301, Telomelysin) in combination with pembrolizumab in gastric and gastroesophageal junction adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, TPS4145-TPS4145.	0.8	4
76	Impact of antibiotic use on response to treatment with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2019, 37, 143-143.	0.8	10
77	Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.. Journal of Clinical Oncology, 2019, 37, 2-2.	0.8	136
78	A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1).. Journal of Clinical Oncology, 2019, 37, 4-4.	0.8	24
79	Abstract A075: A protective role for group 3 innate lymphoid cells in colitis-associated colorectal cancer. , 2019, , .		0
80	Evaluation of intratumoral T cells in biopsies from advanced gastric cancer patients treated with andecaliximab and nivolumab.. Journal of Clinical Oncology, 2019, 37, 118-118.	0.8	0
81	Exploratory evaluation of baseline tumor biomarkers and their association with response and survival in patients with previously treated advanced gastric cancer treated with andecaliximab combined with nivolumab versus nivolumab.. Journal of Clinical Oncology, 2019, 37, 148-148.	0.8	1
82	Evaluation of a REDCap-based Workflow for Supporting Federal Guidance for Electronic Informed Consent. AMIA Summits on Translational Science Proceedings, 2019, 2019, 163-172.	0.4	8
83	Abstract 3817: Systems biology identifies that Gleevec reverses taxane resistance in solid tumors by selective inhibition of a novel +Tip microtubule-binding variant. , 2019, , .		0
84	Being present: oncologists' role in promoting advanced cancer patients' illness understanding. Cancer Medicine, 2018, 7, 1511-1518.	1.3	7
85	Chemotherapy Use, End-of-Life Care, and Costs of Care Among Patients Diagnosed With Stage IV Pancreatic Cancer. Journal of Pain and Symptom Management, 2018, 55, 1113-1121.e3.	0.6	27
86	Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. Clinical Cancer Research, 2018, 24, 3829-3837.	3.2	69
87	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. JAMA Oncology, 2018, 4, e180013.	3.4	1,350
88	Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. Gastric Cancer, 2018, 21, 429-438.	2.7	26
89	Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. Annals of Surgery, 2018, 267, 898-904.	2.1	9
90	ASCO Resource-Stratified Guidelines: Methods and Opportunities. Journal of Global Oncology, 2018, 4, 1-8.	0.5	7

#	ARTICLE	IF	CITATIONS
91	Reply to M. Mo et al. Journal of Clinical Oncology, 2018, 36, 303-303.	0.8	1
92	Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 2545-2556.	0.8	204
93	Oncologic and Palliative Care in a Global Setting in the Twenty-First Century: The Patient, Family, and Oncologic Health Care Team. Journal of Global Oncology, 2018, 4, 1-3.	0.5	0
94	Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncology, The, 2018, 19, 1372-1384.	5.1	319
95	Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies. Blood Coagulation and Fibrinolysis, 2018, 29, 227-230.	0.5	0
96	62 - Shared and Private Genomic Alterations in Colitis-associated Dysplasia and Carcinoma Developing Synchronously within the Same Patient. Gastroenterology, 2018, 154, S-21.	0.6	0
97	Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).. Journal of Clinical Oncology, 2018, 36, 2564-2564.	0.8	1
98	The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2018, 36, 4010-4010.	0.8	19
99	Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study.. Journal of Clinical Oncology, 2018, 36, 4049-4049.	0.8	9
100	RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2018, 36, 5-5.	0.8	19
101	A phase II study of chemotherapy and immune checkpoint blockade with pembrolizumab in the perioperative and maintenance treatment of locoregional gastric or GE junction adenocarcinoma.. Journal of Clinical Oncology, 2018, 36, TPS197-TPS197.	0.8	1
102	KEYNOTE-059 cohort 1: Pembrolizumab (Pembro) monotherapy in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer in patients (Pts) with PD-L1+ tumors—Asian subgroup analysis.. Journal of Clinical Oncology, 2018, 36, 723-723.	0.8	1
103	Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.. Journal of Clinical Oncology, 2018, 36, 4044-4044.	0.8	1
104	Results from a phase I study of andeciximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 3578-3578.	0.8	0
105	Abstract 2086: Comprehensive microbial and immunological screening of gastroesophageal biopsies: A multi-parametric analysis to study carcinogenesis. , 2018, , .		0
106	Abstract B39: Understanding the association of gut microbiota and tumor microenvironment in gastric and esophageal cancer. , 2018, , .		0
107	Abstract A04: Microbial and immunologic characterization of gastroesophageal tissue biopsy samples: A multiparametric analysis. , 2018, , .		0
108	Future Directions in Improving Outcomes for Patients with Gastric and Esophageal Cancer. Hematology/Oncology Clinics of North America, 2017, 31, 545-552.	0.9	7

#	ARTICLE	IF	CITATIONS
109	Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center. <i>Annals of Surgery</i> , 2017, 266, 1006-1012.	2.1	56
110	Early-onset Colorectal Cancer is Distinct From Traditional Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 293-299.e6.	1.0	117
111	The Management of Esophagogastric Cancers Enters a New Era. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, xiii-xiv.	0.9	0
112	Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. <i>Lancet Oncology</i> , The, 2017, 18, 640-653.	5.1	383
113	The Gastric Microbiome and Its Influence on Gastric Carcinogenesis. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 389-408.	0.9	27
114	Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma. <i>JAMA Oncology</i> , 2017, 3, 620.	3.4	233
115	Antibody-drug conjugates: can the payload improve activity in HER2 expressing cancers?. <i>Lancet Oncology</i> , The, 2017, 18, 1433-1434.	5.1	0
116	The gastric microbiota â€” bacterial diversity and implications. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 692-693.	8.2	29
117	Oesophageal cancer. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17048.	18.1	671
118	Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response. <i>Clinical Cancer Research</i> , 2017, 23, 2673-2680.	3.2	49
119	State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Researchâ€™ NCI Strategic Workshop Highlights of Discussion Report. <i>Journal of the National Cancer Institute Monographs</i> , 2017, 2017, .	0.9	10
120	The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction â€” a phase III trial of the German AIO/CAO-V/CAOGI. <i>BMC Cancer</i> , 2017, 17, 893.	1.1	128
121	HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2â€™ Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2558-2567.	0.8	98
122	KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4003.	0.8	134
123	CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3619-TPS3619.	0.8	12
124	A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4139-TPS4139.	0.8	8
125	The â€™RENAISSANCEâ€™ Trial: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junctionâ€™ A phase III trial of the German AIO/CAO-V/CAOGI.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4140-TPS4140.	0.8	1
126	A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4141-TPS4141.	0.8	5

#	ARTICLE	IF	CITATIONS
127	Updated results of a phase I study combining the matrix metalloproteinase 9 inhibitor GS-5745 and mFOLFOX6 in patients with advanced gastric/gastroesophageal junction cancer.. Journal of Clinical Oncology, 2017, 35, 108-108.	0.8	2
128	Analysis of outcomes in metastatic pancreatic cancer: Real-world experience in academic cancer centers.. Journal of Clinical Oncology, 2017, 35, 458-458.	0.8	0
129	A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma.. Journal of Clinical Oncology, 2017, 35, TPS217-TPS217.	0.8	0
130	Impact of early FDG-PET directed intervention on preoperative therapy for locally advanced gastric cancer: A Cooperative Group random assignment phase II study (Alliance A021302) Impac.. Journal of Clinical Oncology, 2017, 35, TPS4135-TPS4135.	0.8	1
131	Abstract 274: Early-onset colorectal cancer is distinct from traditional colorectal cancer. , 2017, , .		0
132	Abstract 4169: A novel, short isoform of the +Tip microtubule binding protein CLIP170 confers taxane resistance in gastric cancer. , 2017, , .		0
133	Reply to O.O. Eren et al and S. Mikhail. Journal of Clinical Oncology, 2016, 34, 2068-2069.	0.8	0
134	Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. Gastroenterology, 2016, 151, 278-287.e6.	0.6	147
135	A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction. Oncologist, 2016, 21, 1085-1090.	1.9	82
136	Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: A multicentre analysis. European Journal of Cancer, 2016, 63, 189-200.	1.3	40
137	Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 2784-2796.	0.8	267
138	Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 2654-2668.	0.8	292
139	Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. Journal of Clinical Oncology, 2016, 34, 843-853.	0.8	128
140	Results of a phase I study of GS-5745 in combination with mFOLFOX in patients with advanced unresectable gastric / GE junction tumors.. Journal of Clinical Oncology, 2016, 34, 4033-4033.	0.8	3
141	The messenger matters: Relative influence of oncologists versus other care team members on advanced cancer patients' illness understanding.. Journal of Clinical Oncology, 2016, 34, 6545-6545.	0.8	1
142	A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, TPS4132-TPS4132.	0.8	4
143	The BRIGHTER trial: A phase III randomized double-blind study of BBI-608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, TPS4144-TPS4144.	0.8	3
144	A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).. Journal of Clinical Oncology, 2016, 34, TPS178-TPS178.	0.8	2

#	ARTICLE	IF	CITATIONS
145	Pembrolizumab (MK-3475) for previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase II KEYNOTE-180 study.. Journal of Clinical Oncology, 2016, 34, TPS189-TPS189.	0.8	3
146	Chemotherapy, acute health care events, and hospice use among stage IV pancreatic cancer patients.. Journal of Clinical Oncology, 2016, 34, 6574-6574.	0.8	0
147	Phase I study of BPM 31510 in advanced solid tumors: Omics-based molecular correlation to outcome for patient stratification.. Journal of Clinical Oncology, 2016, 34, 2550-2550.	0.8	1
148	Abstract 2932: Impaired taxane binding to MT pore sites mediates intrinsic drug resistance in diffuse gastric cancer. , 2016, , .		0
149	Abstract 3295: Microbiome profiling and immunological characterization on gastrointestinal tract tumors. , 2016, , .		0
150	Lessons from the first ecancer symposium on angiogenesis in gastric cancer. Ecancermedicalsecience, 2015, 9, 553.	0.6	0
151	Identification of low abundance microbiome in clinical samples using whole genome sequencing. Genome Biology, 2015, 16, 265.	3.8	90
152	Update on Metastatic Gastric and Esophageal Cancers. Journal of Clinical Oncology, 2015, 33, 1760-1769.	0.8	181
153	Chemoradiation in oesophageal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 193-209.	1.0	16
154	Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. Journal of Clinical Oncology, 2015, 33, 3874-3879.	0.8	155
155	Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience.. Journal of Clinical Oncology, 2015, 33, 3546-3546.	0.8	5
156	Time-dependent patterns of recurrence and death in resected colon cancer (CC): Pooled analysis of 12,223 patients from modern trials in the ACCENT database containing oxaliplatin.. Journal of Clinical Oncology, 2015, 33, 3593-3593.	0.8	1
157	METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).. Journal of Clinical Oncology, 2015, 33, 4012-4012.	0.8	72
158	Phase I study of GS-5745 alone and in combination with chemotherapy in patients with advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 4030-4030.	0.8	5
159	A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).. Journal of Clinical Oncology, 2015, 33, TPS4131-TPS4131.	0.8	4
160	The BRIGHTER trial: A phase III randomized double-blind study of BBI608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2015, 33, TPS4139-TPS4139.	0.8	8
161	False-negative rate for HER2 testing in 738 gastric and gastroesophageal junction cancers (GEC) from two global randomized clinical trials.. Journal of Clinical Oncology, 2015, 33, 16-16.	0.8	17
162	Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC).. Journal of Clinical Oncology, 2015, 33, 2-2.	0.8	23

#	ARTICLE	IF	CITATIONS
163	Chemotherapy toxicity predicted by baseline nutrition assessment in gastrointestinal (GI) malignancies: A multicenter analysis.. Journal of Clinical Oncology, 2015, 33, 410-410.	0.8	1
164	Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers.. Journal of Clinical Oncology, 2015, 33, 703-703.	0.8	4
165	Identification of the gastric microbiome from endoscopic biopsy samples using whole genome sequencing.. Journal of Clinical Oncology, 2015, 33, 8-8.	0.8	0
166	Phase 1 study of BPM 31510 (Ubidecarenone) in patients with advanced solid tumors (ST): Use of multiomics platform to evaluate reversal of Warburg effect.. Journal of Clinical Oncology, 2015, 33, 2539-2539.	0.8	0
167	Association of high tumor infiltrating cytotoxic T cells with absence of lymph node involvement in resected colorectal and gastric cancer: Implications for immunosurveillance.. Journal of Clinical Oncology, 2015, 33, 4068-4068.	0.8	0
168	“Months, Not Years” Impact of Clinical Discussions of Advanced Cancer Life-Expectancy on Patient Illness Understanding.. Journal of Clinical Oncology, 2015, 33, 9549-9549.	0.8	0
169	“Months, not years” Impact of clinical discussions of advanced cancer life-expectancy on patient illness understanding.. Journal of Clinical Oncology, 2015, 33, 30-30.	0.8	0
170	Gastric cancer drug trials “are women second class citizens?”. Nature Reviews Clinical Oncology, 2014, 11, 438-438.	12.5	1
171	The germline CDH1 c.48 G > C substitution contributes to cancer predisposition through generation of a pro-invasive mutation. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 770, 106-111.	0.4	11
172	Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 126-130.	0.6	6
173	The Role of 18F-FDG PET Imaging in Upper Gastrointestinal Malignancies. Current Treatment Options in Oncology, 2014, 15, 351-364.	1.3	11
174	Targeted therapies in gastric cancer “the dawn of a new era. Nature Reviews Clinical Oncology, 2014, 11, 10-11.	12.5	37
175	IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Trop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.. Journal of Clinical Oncology, 2014, 32, 3032-3032.	0.8	7
176	Evaluation of PET response to neoadjuvant therapy for patients with gastric and GEJ adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 114-114.	0.8	0
177	Phase I study of epigenetic priming using azacitidine prior to neoadjuvant chemotherapy in patients with resectable esophageal and gastric adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 4047-4047.	0.8	0
178	Whole-genome sequencing (WGS) to identify <i>H. pylori</i> and its impact on the gastric microbiome.. Journal of Clinical Oncology, 2014, 32, 11070-11070.	0.8	0
179	Preoperative chemoradiation versus preoperative chemotherapy alone for esophageal cancer: Higher response rates but equivalent survival.. Journal of Clinical Oncology, 2014, 32, 4071-4071.	0.8	0
180	The development of bevacizumab in noncolorectal gastrointestinal malignancies: gastroesophageal, pancreatic, and hepatocellular carcinoma. Clinical Advances in Hematology and Oncology, 2014, 12, 239-46.	0.3	3

#	ARTICLE	IF	CITATIONS
181	Met, IGF1R, and Other New Targets in Upper GI Malignancies. Current Treatment Options in Oncology, 2013, 14, 321-336.	1.3	2
182	Gastric cancer epidemiology and risk factors. Journal of Surgical Oncology, 2013, 107, 230-236.	0.8	412
183	Capecitabine in the treatment of esophageal and gastric cancers. Expert Opinion on Investigational Drugs, 2013, 22, 1645-1657.	1.9	10
184	Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS ONE, 2013, 8, e54014.	1.1	174
185	Phase I/II trial of intraperitoneal implantation of agarose-agarose macrobeads (MB) containing mouse renal adenocarcinoma cells (RENCA) in patients (pts) with advanced colorectal cancer (CRC).. Journal of Clinical Oncology, 2013, 31, e14517-e14517.	0.8	2
186	MetGastric: A randomized phase III study of onartuzumab (MetMab) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction.. Journal of Clinical Oncology, 2013, 31, TPS4155-TPS4155.	0.8	13
187	A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2013, 31, 450-450.	0.8	7
188	A case report of trastuzumab dose in gastric cancer. Journal of Gastrointestinal Oncology, 2013, 4, E19-22.	0.6	6
189	Clinical and preclinical evaluation of taxane sensitivity in gastric cancer (GC): Relevance of GC histology.. Journal of Clinical Oncology, 2013, 31, 37-37.	0.8	0
190	Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and prolonged stable disease observed in adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, 91-91.	0.8	1
191	Phase II study of preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in patients with locally advanced gastric and GEJ adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, 94-94.	0.8	0
192	The incidence and impact of poor nutrition in gastrointestinal malignancies.. Journal of Clinical Oncology, 2013, 31, e20549-e20549.	0.8	0
193	Effect of CTCAE v4 grading of hypertension on reported toxicity in advanced cancer patients receiving vascular endothelial growth factor (VEGF)-targeting agents.. Journal of Clinical Oncology, 2013, 31, e15600-e15600.	0.8	1
194	Variable penetrance of CDH1 mutation diffuse gastric cancer: A genomic analysis.. Journal of Clinical Oncology, 2013, 31, 4082-4082.	0.8	0
195	Preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in locally advanced gastroesophageal junction and gastric adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, 4101-4101.	0.8	1
196	Management of advanced gastric cancer. Expert Review of Gastroenterology and Hepatology, 2012, 6, 199-209.	1.4	69
197	Treatment of resectable gastric cancer. Therapeutic Advances in Gastroenterology, 2012, 5, 49-69.	1.4	70
198	Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial. Journal of Clinical Oncology, 2012, 30, 2119-2127.	0.8	434

#	ARTICLE	IF	CITATIONS
199	Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. <i>Cancer</i> , 2012, 118, 3053-3061.	2.0	85
200	A prospective evaluation of the utility of <sup>18</sup> F-fluoro-2-deoxyglucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. <i>Cancer</i> , 2012, 118, 5481-5488.	2.0	122
201	A multicenter random assignment phase II study of irinotecan and flavopiridol versus irinotecan alone for patients with p53 wild-type gastric adenocarcinoma (NCI 8060).. <i>Journal of Clinical Oncology</i> , 2012, 30, e14586-e14586.	0.8	3
202	Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 67-67.	0.8	3
203	Will Disease Heterogeneity Help Define Treatment Paradigms for Gastroesophageal Adenocarcinoma? A Global Perspective. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 256-259.	1.8	0
204	Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3968-3976.	0.8	1,003
205	Human Epidermal Growth Factor Receptor 2 Testing in Gastroesophageal Cancer: Correlation Between Immunohistochemistry and Fluorescence In Situ Hybridization. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 1460-1465.	1.2	61
206	A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. <i>Investigational New Drugs</i> , 2011, 29, 1475-1481.	1.2	45
207	Molecular Classification of Gastric Cancer: A New Paradigm. <i>Clinical Cancer Research</i> , 2011, 17, 2693-2701.	3.2	287
208	<i>MET</i> Expression and Amplification in Patients with Localized Gastric Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1021-1027.	1.1	141
209	Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 868-874.	0.8	174
210	Role of <sup>18</sup> F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies. <i>World Journal of Gastroenterology</i> , 2011, 17, 5059.	1.4	51
211	Comparison of Gastric Cancer Survival Following R0 Resection in the United States and Korea Using an Internationally Validated Nomogram. <i>Annals of Surgery</i> , 2010, 251, 640-646.	2.1	314
212	Gastric Cancer: A Primer on the Epidemiology and Biology of the Disease and an Overview of the Medical Management of Advanced Disease. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 437-447.	2.3	164
213	A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 1113-1121.	1.1	25
214	Upper Gastrointestinal Cancer Predisposition Syndromes. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 815-835.	0.9	12
215	Advanced gastric cancer – Slow but steady progress. <i>Cancer Treatment Reviews</i> , 2010, 36, 384-392.	3.4	141
216	Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 7405-7411.	3.2	44

#	ARTICLE	IF	CITATIONS
217	Endoscopic Ultrasound Can Improve the Selection for Laparoscopy in Patients with Localized Gastric Cancer. <i>Journal of the American College of Surgeons</i> , 2009, 208, 173-178.	0.2	76
218	Perineural Invasion After Preoperative Chemotherapy Predicts Poor Survival in Patients With Locally Advanced Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 356-362.	0.6	18
219	Phase II trial of sequential paclitaxel and 1Âh infusion of bryostatin-1 in patients with advanced esophageal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 875-880.	1.1	50
220	HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3499-3508.	1.9	121
221	Does Graded Histologic Response After Neoadjuvant Chemotherapy Predict Survival for Completely Resected Gastric Cancer?. <i>Annals of Surgical Oncology</i> , 2007, 14, 3412-3418.	0.7	95
222	Incorporation of biologic therapies in the management of gastroesophageal cancers. <i>Gastrointestinal Cancer Research: GCR</i> , 2007, 1, S22-9.	0.8	0
223	Cyclin dependent kinases as targets for cancer therapy. <i>Update on Cancer Therapeutics</i> , 2006, 1, 311-332.	0.9	6
224	Gastric cancer: An update. <i>Current Oncology Reports</i> , 2006, 8, 183-191.	1.8	9
225	Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 5201-5206.	0.8	402
226	A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol. <i>Clinical Cancer Research</i> , 2005, 11, 3836-3845.	3.2	109
227	Drg1 Expression in 131 Colorectal Liver Metastases: Correlation with Clinical Variables and Patient Outcomes. <i>Clinical Cancer Research</i> , 2005, 11, 3296-3302.	3.2	61
228	Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 1875-1884.	0.8	113
229	Thromboembolic Events in Gastric Cancer: High Incidence in Patients Receiving Irinotecan- and Bevacizumab-Based Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 2574-2576.	0.8	120
230	Targeting the Cell Cycle: A New Approach to Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 9408-9421.	0.8	703
231	Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry. <i>Journal of Clinical Oncology</i> , 2005, 23, 1803-1810.	0.8	1,050
232	Cyclin-dependent kinases as targets for cancer therapy. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, 22, 135-162.	0.5	18
233	Treatment of metastatic esophagus and gastric cancer. <i>Seminars in Oncology</i> , 2004, 31, 574-587.	0.8	43
234	Combined Modality Therapy of Esophageal Cancer: Changes in the Standard of Care?. <i>Annals of Surgical Oncology</i> , 2004, 11, 641-643.	0.7	14

#	ARTICLE	IF	CITATIONS
235	Cyclin-dependent kinases as targets for cancer therapy. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003, 21, 145-170.	0.5	15
236	Recent developments in the treatment of gastric carcinoma. <i>Current Oncology Reports</i> , 2002, 4, 193-201.	1.8	7
237	The relevance of drug sequence in combination chemotherapy. <i>Drug Resistance Updates</i> , 2000, 3, 335-356.	6.5	40